FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3169314347> ?p ?o ?g. }

• W3169314347 endingPage "108123" @default.
• W3169314347 startingPage "108123" @default.
• W3169314347 abstract "The failures in the treatment of leishmaniasis is an increasing problem around the world, especially related to resistance. Thus, we describe the synthesis and in vivo anti-Leishmania activity of alkylphosphocholine and alkyltriazoles; besides, their likely action mechanisms stem from some eventual inhibition of parasite enzymes using computational tools. These compounds were tested in an in vivo hamster model infected with Leishmania Leishmania infantum chagasi. Fifty days after parasite inoculation, the two compounds 12-azidedodecylphosphocholine (3) and 3-(1-(12-fluorododecyl)-1H-1,2,3-triazol-1-yl)propano-1-ol (9), were separately administered once a day as oral suspensions (25 and 12.5 mg/kg/day, respectively) during ten days, and their efficacy was compared to the reference compound pentavalent antimonial Glucantime (GLU). Compound 3 significantly reduced the number of parasites in the spleen (4.93 × 102 amastigotes/g) and liver (4.52 × 103 amastigotes/g). Compound 9 reduced the number of amastigotes in the spleen to 1.30 × 104 and 1.36 × 103 amastigotes/g in the liver. GLU was the most effective overall treatment (7.50 × 101 and 2.28 × 102 amastigotes/g in the spleen and liver, respectively). The high activity levels of these compounds in vivo may stem from their high in vitro leishmanicidal activity and lipophilicity. The in silico absorption, distribution, metabolism, and excretion studies also showed some anti-Leishmania potential. Compound 9 had more lipophilic characteristics than those of compound 3. In silico studies of the nine enzymes of compounds 3 and 9 showed significant evidence of interactions with nicotimidase and tyrosine aminotransferase, demonstrating possible inhibition enzymes present in L. (L.) infantum chagasi. These compounds could be a promising template for developing a new class of leishmanicidal agents, by oral route, and deserve further investigation to explore different therapeutic regimens." @default.
• W3169314347 created "2021-06-22" @default.
• W3169314347 creator A5008752634 @default.
• W3169314347 creator A5009168803 @default.
• W3169314347 creator A5013280993 @default.
• W3169314347 creator A5023168766 @default.
• W3169314347 creator A5035842049 @default.
• W3169314347 creator A5053246254 @default.
• W3169314347 creator A5061642955 @default.
• W3169314347 creator A5074317724 @default.
• W3169314347 creator A5074591688 @default.
• W3169314347 creator A5076066390 @default.
• W3169314347 date "2021-07-01" @default.
• W3169314347 modified "2023-10-18" @default.
• W3169314347 title "In vivo evaluation of anti-Leishmania activity of alkyltriazoles and alkylphosphocholines by oral route" @default.
• W3169314347 cites W1139037058 @default.
• W3169314347 cites W1618133922 @default.
• W3169314347 cites W1967441075 @default.
• W3169314347 cites W1969009533 @default.
• W3169314347 cites W1986397806 @default.
• W3169314347 cites W1991674117 @default.
• W3169314347 cites W1997696660 @default.
• W3169314347 cites W2004875218 @default.
• W3169314347 cites W2012449370 @default.
• W3169314347 cites W2013758900 @default.
• W3169314347 cites W2022112153 @default.
• W3169314347 cites W2027136518 @default.
• W3169314347 cites W2036543628 @default.
• W3169314347 cites W2041133307 @default.
• W3169314347 cites W2062104910 @default.
• W3169314347 cites W2066434469 @default.
• W3169314347 cites W2070103454 @default.
• W3169314347 cites W2082383834 @default.
• W3169314347 cites W2084889403 @default.
• W3169314347 cites W2085611537 @default.
• W3169314347 cites W2089741724 @default.
• W3169314347 cites W2113189468 @default.
• W3169314347 cites W2116856707 @default.
• W3169314347 cites W2122428796 @default.
• W3169314347 cites W2126812590 @default.
• W3169314347 cites W2130479394 @default.
• W3169314347 cites W2139779243 @default.
• W3169314347 cites W2270144407 @default.
• W3169314347 cites W2402258526 @default.
• W3169314347 cites W2596180243 @default.
• W3169314347 cites W2746676899 @default.
• W3169314347 cites W2793344804 @default.
• W3169314347 cites W2795782826 @default.
• W3169314347 cites W2885034824 @default.
• W3169314347 cites W2893986419 @default.
• W3169314347 cites W2897129981 @default.
• W3169314347 cites W2902115282 @default.
• W3169314347 cites W2953387989 @default.
• W3169314347 cites W2971822321 @default.
• W3169314347 cites W3008570399 @default.
• W3169314347 cites W3027005219 @default.
• W3169314347 cites W3044076536 @default.
• W3169314347 cites W3085018661 @default.
• W3169314347 cites W3093536259 @default.
• W3169314347 cites W3097828592 @default.
• W3169314347 cites W651521406 @default.
• W3169314347 cites W3044544192 @default.
• W3169314347 doi "https://doi.org/10.1016/j.exppara.2021.108123" @default.
• W3169314347 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34144040" @default.
• W3169314347 hasPublicationYear "2021" @default.
• W3169314347 type Work @default.
• W3169314347 sameAs 3169314347 @default.
• W3169314347 citedByCount "1" @default.
• W3169314347 countsByYear W31693143472022 @default.
• W3169314347 crossrefType "journal-article" @default.
• W3169314347 hasAuthorship W3169314347A5008752634 @default.
• W3169314347 hasAuthorship W3169314347A5009168803 @default.
• W3169314347 hasAuthorship W3169314347A5013280993 @default.
• W3169314347 hasAuthorship W3169314347A5023168766 @default.
• W3169314347 hasAuthorship W3169314347A5035842049 @default.
• W3169314347 hasAuthorship W3169314347A5053246254 @default.
• W3169314347 hasAuthorship W3169314347A5061642955 @default.
• W3169314347 hasAuthorship W3169314347A5074317724 @default.
• W3169314347 hasAuthorship W3169314347A5074591688 @default.
• W3169314347 hasAuthorship W3169314347A5076066390 @default.
• W3169314347 hasBestOaLocation W31693143471 @default.
• W3169314347 hasConcept C136764020 @default.
• W3169314347 hasConcept C150903083 @default.
• W3169314347 hasConcept C202751555 @default.
• W3169314347 hasConcept C203014093 @default.
• W3169314347 hasConcept C207001950 @default.
• W3169314347 hasConcept C2776555147 @default.
• W3169314347 hasConcept C2778689377 @default.
• W3169314347 hasConcept C2780931953 @default.
• W3169314347 hasConcept C2781092759 @default.
• W3169314347 hasConcept C2781257258 @default.
• W3169314347 hasConcept C41008148 @default.
• W3169314347 hasConcept C55493867 @default.
• W3169314347 hasConcept C71928629 @default.
• W3169314347 hasConcept C86803240 @default.
• W3169314347 hasConcept C89423630 @default.
• W3169314347 hasConcept C98274493 @default.
• W3169314347 hasConcept C98319499 @default.

• next